Understanding Acute Myeloid Leukemia Induction with '7+3'…

What is Acute Myeloid Leukemia (AML)?

Acute myeloid leukemia (AML) is a type of cancer that starts in the bone marrow and leads to the production of abnormal white blood cells. These cells, called blasts, do not function properly and can accumulate, crowding out healthy blood cells.

The disease progresses rapidly, making prompt and effective treatment essential for patient survival.

The '7+3' Induction Chemotherapy Protocol

The '7+3' protocol is a standard induction chemotherapy regimen used to treat AML. It consists of seven days of cytarabine (Ara-C) and three days of daunorubicin or idarubicin.

This combination aims to rapidly kill the leukemic cells while minimizing damage to healthy cells.

live demo · related simulation● LIVE

Mechanisms of Action

Cytaurabine inhibits DNA synthesis, preventing the growth and division of cancer cells. Daunorubicin or idarubicin are anthracycline antibiotics that intercalate into DNA, causing strand breaks and leading to cell death.

Together, these drugs target different aspects of cell replication, enhancing their effectiveness in eradicating leukemic cells.

Efficacy and Side Effects

The '7+3' protocol has shown significant efficacy in achieving complete remission rates for AML patients. However, it also carries substantial side effects such as bone marrow suppression, infections, and cardiotoxicity.

Despite these challenges, the protocol remains a cornerstone of AML treatment due to its proven outcomes.

Frequently asked questions

What is the significance of '7+3' in AML treatment?

'7+3' refers to the standard chemotherapy regimen used for induction therapy in acute myeloid leukemia, consisting of seven days of cytarabine and three days of daunorubicin or idarubicin.

Why is the '7+3' protocol still used despite newer treatments?

'7+3' remains a benchmark due to its proven efficacy in achieving remission, although it may be combined with other therapies or replaced by more targeted approaches depending on patient characteristics and disease subtype.

What are the common side effects of '7+3' chemotherapy?

Common side effects include bone marrow suppression leading to anemia, infections, and thrombocytopenia; nausea; vomiting; and cardiotoxicity from anthracycline drugs.

How does the '7+3' protocol compare with other AML treatments?

'7+3' is a well-established induction therapy but may be adapted or combined with newer targeted therapies, immunotherapies, and supportive care to improve outcomes for patients.

Try it live

Everything above runs in your browser — open Acute Myeloid Leukemia Induction "7+3" Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Acute Myeloid Leukemia Induction "7+3" Simulator simulation

Understanding Acute Myeloid Leukemia Induction with '7+3' Chemotherapy